Budiodarone HCl | CAS#478941-80-9 | antiarrhythmic

MedKoo Cat#: 319821 | Name: Budiodarone HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Budiodarone, also known as ATI-2042, is an antiarrhythmic agent and chemical analog of amiodarone. Budiodarone has a half life of 7 h. It is electrophysiologically similar to amiodarone, but may not have metabolic and interaction side effects. ATI-2042 effectively reduced AFB over all doses studied by reducing mean episode duration. Budiodarone holds much promise as an antiarrhythmic drug to prevent fibrillation. As a drug that spans over many of antiarrhythmic drug classes, the electrophysiological activity of budiodarone includes.

Chemical Structure

Budiodarone HCl

CAS#478941-80-9 (HCl)

Theoretical Analysis

MedKoo Cat#: 319821

Name: Budiodarone HCl

CAS#: 478941-80-9 (HCl)

Chemical Formula: C27H32ClI2NO5

Exact Mass: 703.0292

Molecular Weight: 739.81

Elemental Analysis: C, 43.83; H, 4.36; Cl, 4.79; I, 34.31; N, 1.89; O, 10.81

Price and Availability

Size	Price	Availability
1mg	USD 150.00	Ready to ship
5mg	USD 450.00	Ready to ship
10mg	USD 750.00	Ready to ship
25mg	USD 1,250.00	Ready to ship
50mg	USD 1,950.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

478941-80-9 (HCl) 478941-93-4 (tartrate) 335148-45-3 (free base) 478941-90-1 (maleate) 478941-86-5 (fumarate) 478941-98-9 (citrate)

Synonym

Budiodarone HCl; Budiodarone hydrochloride; (S)-ATI 2042; ATI-2042; ATI2042; ATI 2042; Budiodarone;

IUPAC/Chemical Name

(S)-sec-butyl 2-(3-(4-(2-(diethylamino)ethoxy)-3,5-diiodobenzoyl)benzofuran-2-yl)acetate hydrochloride

InChi Key

WDMVNERQUKWYOA-LMOVPXPDSA-N

InChi Code

InChI=1S/C27H31I2NO5.ClH/c1-5-17(4)34-24(31)16-23-25(19-10-8-9-11-22(19)35-23)26(32)18-14-20(28)27(21(29)15-18)33-13-12-30(6-2)7-3;/h8-11,14-15,17H,5-7,12-13,16H2,1-4H3;1H/t17-;/m0./s1

SMILES Code

O=C(O[C@@H](C)CC)CC1=C(C(C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)=O)C3=CC=CC=C3O1.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Amiodarone is considered the most effective antiarrhythmic drug available, but its adverse side effects, including hepatic, pulmonary and thyroid toxicity as well as multiple drug interactions,[4] are discouraging its use. Budiodarone only differs in structure from amiodarone through the presence of a sec-butyl acetate side chain at position 2 of the benzofuran moiety. This side chain allows for budiodarone to have a shorter half-life in the body than amiodarone (7 hours versus 35–68 days) which allows it to have a faster onset of action and metabolism while still maintaining similar electrophysiological activity. The faster metabolism of budiodarone allows for fewer adverse side effects than amiodarone principally due to decreased levels of toxicity in the body.

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#Y23X03M10

QC Data

View QC data: current batch, Lot#Y23X03M10

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

Budiodarone, also known as ATI-2042, is an antiarrhythmic agent and chemical analog of amiodarone.

In vitro activity:

TBD

In vivo activity:

TBD

Preparing Stock Solutions

The following data is based on the product molecular weight 739.81 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

TBD

In vitro protocol:

TBD

In vivo protocol:

TBD

1: Bunch TJ, Anderson JL. Adjuvant antiarrhythmic therapy in patients with implantable cardioverter defibrillators. Am J Cardiovasc Drugs. 2014 Apr;14(2):89-100. doi: 10.1007/s40256-013-0056-x. PMID: 24288157. 2: Whitehead DM, Hartmann S, Ilyas T, Taylor KR, Kohler AD, Ellames GJ. A convenient method to produce [(14) C]carbon monoxide and its application to the radiosynthesis of [carboxyl-(14) C]celivarone, [carboxyl-(14) C]SSR149744. J Labelled Comp Radiopharm. 2013 Feb;56(2):36-41. doi: 10.1002/jlcr.3009. Epub 2013 Jan 22. PMID: 24285280. 3: Khitri AR, Aliot EM, Capucci A, Connolly SJ, Crijns H, Hohnloser SH, Kulakowski P, Roy D, Radzik D, Kowey PR. Celivarone for maintenance of sinus rhythm and conversion of atrial fibrillation/flutter. J Cardiovasc Electrophysiol. 2012 May;23(5):462-72. doi: 10.1111/j.1540-8167.2011.02234.x. Epub 2011 Dec 15. PMID: 22171925. 4: Kowey PR, Crijns HJ, Aliot EM, Capucci A, Kulakowski P, Radzik D, Roy D, Connolly SJ, Hohnloser SH; ALPHEE Study Investigators. Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter- defibrillator interventions or death: the ALPHEE study. Circulation. 2011 Dec 13;124(24):2649-60. doi: 10.1161/CIRCULATIONAHA.111.072561. Epub 2011 Nov 14. PMID: 22082672. 5: Gojkovic O, Aliot EM, Capucci A, Connolly SJ, Crijns H, Hohnloser SH, Kulakowski P, Roy D, Radzik D, Singh BN, Kowey PR. Celivarone in patients with an implantable cardioverter-defibrillator: adjunctive therapy for the reduction of ventricular arrhythmia-triggered implantable cardioverter-defibrillator interventions. Heart Rhythm. 2012 Feb;9(2):217-224.e2. doi: 10.1016/j.hrthm.2011.09.073. Epub 2011 Oct 4. PMID: 21978965. 6: Gramley F, Himmrich E, Mollnau H, Theis C, Hammwohner M, Goette A. Recent advances in the pharmacological treatment of cardiac arrythmias. Drugs Today (Barc). 2009 Nov;45(11):807-24. doi: 10.13581/dot.2009.45.11.1412574. Erratum in: Drugs Today (Barc). 2010 Jan;46(1):69. PMID: 20126673. 7: Mason PK, DiMarco JP. New pharmacological agents for arrhythmias. Circ Arrhythm Electrophysiol. 2009 Oct;2(5):588-97. doi: 10.1161/CIRCEP.109.884429. PMID: 19843928. 8: Verma A. Alternatives to amiodarone: search for the Holy Grail. Europace. 2009 Apr;11(4):402-4. doi: 10.1093/europace/eup042. Epub 2009 Feb 17. PMID: 19223364. 9: Arya A, Silberbauer J, Teichman SL, Milner P, Sulke N, Camm AJ. A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology. Europace. 2009 Apr;11(4):458-64. doi: 10.1093/europace/eun384. Epub 2009 Jan 26. PMID: 19174378; PMCID: PMC2659603. 10: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 May;30(4):313-31. PMID: 18773127. 11: Han TS, Williams GR, Vanderpump MP. Benzofuran derivatives and the thyroid. Clin Endocrinol (Oxf). 2009 Jan;70(1):2-13. doi: 10.1111/j.1365-2265.2008.03350.x. Epub 2008 Aug 22. PMID: 18727707. 12: Naccarelli GV, Wolbrette DL, Samii S, Banchs JE, Penny-Peterson E, Gonzalez MD. New antiarrhythmic treatment of atrial fibrillation. Expert Rev Cardiovasc Ther. 2007 Jul;5(4):707-14. doi: 10.1586/14779072.5.4.707. PMID: 17605649. 13: Gautier P, Serre M, Cosnier-Pucheu S, Djandjighian L, Roccon A, Herbert JM, Nisato D. In vivo and in vitro antiarrhythmic effects of SSR149744C in animal models of atrial fibrillation and ventricular arrhythmias. J Cardiovasc Pharmacol. 2005 Feb;45(2):125-35. doi: 10.1097/01.fjc.0000151899.03379.76. PMID: 15654261. 14: Gautier P, Guillemare E, Djandjighian L, Marion A, Planchenault J, Bernhart C, Herbert JM, Nisato D. In vivo and in vitro characterization of the novel antiarrhythmic agent SSR149744C: electrophysiological, anti-adrenergic, and anti-angiotensin II effects. J Cardiovasc Pharmacol. 2004 Aug;44(2):244-57. doi: 10.1097/00005344-200408000-00015. PMID: 15243307. 15: Morey TE, Seubert CN, Raatikainen MJ, Martynyuk AE, Druzgala P, Milner P, Gonzalez MD, Dennis DM. Structure-activity relationships and electrophysiological effects of short-acting amiodarone homologs in guinea pig isolated heart. J Pharmacol Exp Ther. 2001 Apr;297(1):260-6. PMID: 11259553.